Skip to main content

Table 2 Secondary outcome measures

From: Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open-label study

  Baseline (n = 6) Month 1 (n = 6) Month 2 (n = 6) Month 3
(n = 6)
Month 6 (n = 4) Month 9 (n = 4) Month 12 (n = 4)
Oral ulcer number 3.5 (2–5) 0.5 (0–3) 1.5 (0–3) 1.5 (0–5) 0.5 (0–2) 0 (0–1) 0.5 (0–1)
Genital ulcer number 0 (0–3) 0 (0–2) 0 (0–2) 0 (0) 0 (0) 0 (0) 0 (0)
Physician global VAS (0–100) 16.5 (12–79) 13 (6–39) 18.5 (10–32) 14.5 (4–23) 8.5 (7–24) 7.5 (1–58) 14 (3–30)
Patient global VAS (0–100) 73.5 (9–90) 32 (3–92) 48 (0–95) 68.5 (14–88) 51.5 (3–91) 22 (14–53) 35 (23–55)
BDCAF (0–12) 6 (5–11) 6.5 (3–8) 5 (3–8) 5.5 (3–10) 5 (4–6) 5 (1–6) 6 (3–7)
BSAS (0–100) 46 (22–80.5) 34 (19.5–49) 42 (20.5–58) 24.7 (9.5–52) 21.3 (0–44) 24.5 (8.5–30) 33 (15–57)
BDQOL (0–30) 16 (10–24) 10.5 (0–21) 10 (1–23) 14 (0–22) 9.5 (0–22) 6 (3–14) 14 (6–15)
  1. All results are presented as median (range). VAS visual analog scale, BDCAF Behçet’s Disease Current Activity Form, BSAS Behçet’s Syndrome Activity Score, BDQOL Behçet’s Disease Quality of Life